Latest Chai Discovery news, funding rounds and robotics & AI coverage. $800M raised. 2 articles tracked by The Robotics Media.
Chai Discovery is an AI-native drug discovery company founded in 2024 in San Francisco by Joshua Meier, Jack Dent, Matthew McPartlon and Jacques Boitreaud. Its models generate new molecular designs from scratch and predict molecular interactions, letting pharma teams pursue targets that traditional discovery methods have struggled to reach.
Chai has active engagements with Eli Lilly, Pfizer and Novartis, and its latest model Chai-3 materially improves antibody binding affinity over the 2025-era Chai-2. In July 2026 the company raised a $400M Series C at a $3.8B valuation, led by Index Ventures with participation from Kleiner Perkins, Sequoia Capital, Dimension, OpenAI and others.